Home > Journals > Minerva Chirurgica > Past Issues > Minerva Chirurgica 2001 August;56(4) > Minerva Chirurgica 2001 August;56(4):337-44

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CHIRURGICA

A Journal on Surgery


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,115


eTOC

 

ORIGINAL ARTICLES  


Minerva Chirurgica 2001 August;56(4):337-44

Copyright © 2001 EDIZIONI MINERVA MEDICA

language: Italian

New trends in multimodal therapy of primitive gastric lymphoma

Franciosi C. M., Angelini C., Mussi C., Sartori P., Romano F., De Fina S., Uggeri F.


PDF  


Background. Primitive gastric lymphoma (PGL) is a rare tumour, and although its incidence is rising it is difficult to state the role of the various therapeutic methods in treating this disease. Aim of this study is to point out what sequence of treatment is more effective trying to find out some guidelines which can be useful in clinical practice.
Methods. Retrospective analysis of clinical data of 54 patients with PGL admitted at a University surgical department during 10 years. All the patients underwent neoadjuvant or adjuvant chemotherapy and D2 gastrectomy. Follow-up ranged from 6 to 120 months. Survival was related to: Mushoff's stage of disease, the grade according to the Working Formulation and the sequence of treatment. Statistical analysis was performed by Kaplan-Maier method and the difference between survival curves was compared by log-rank test.
Results. Mean postoperative hospital stay was 12 days and morbidity was 18%. Five and 10 years overall survival rates were 70 and 85%. There was a significant difference in survival between patients with high grade PGL and those with intermediate grade (p=0.0188) as well as in those with low grade (p=0.0435). Patients in stages IE-II1E had a significantly longer survival than those in stages IIIE-IVE (p=0.0123). Patients in stages IE-II1E underwent neadjuvant chemotherapy and surgery and survived longer than those in whom surgery preceded chemotherapy (p=0.0293) instead for patients in stages IIIE-IVE neoadjuvant chemotherapy shortened survival (p=0.0403).
Conclusions. In personal opinion, in patients in stages IE-II1E chemotherapy should be carried out before surgery, while in those in stages IIIE-IVE the reverse scheme is more effective in achieving longer survival rates.

top of page

Publication History

Cite this article as

Corresponding author e-mail